Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
about
Therapeutic Targeting of TelomeraseRoles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapiesTargeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promisesHave lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?Systemic Chemotherapy in Advanced Pancreatic CancerTargeting inflammation in pancreatic cancer: Clinical translationFrom bench to bedside a comprehensive review of pancreatic cancer immunotherapy.Viro-immune therapy: A new strategy for treatment of pancreatic cancerVariations in telomere maintenance and the role of telomerase inhibition in gastrointestinal cancerRNA-Based Vaccines in Cancer ImmunotherapyAn Investigation of the Shortcomings of the CONSORT 2010 Statement for the Reporting of Group Sequential Randomised Controlled Trials: A Methodological Systematic ReviewImmunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trialsInterest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer VaccineTelomere biology: Rationale for diagnostics and therapeutics in cancerPancreatic cancer: optimizing treatment options, new, and emerging targeted therapiesVirotherapy: cancer gene therapy at last?The Telomerase-Derived Anticancer Peptide Vaccine GV1001 as an Extracellular Heat Shock Protein-Mediated Cell-Penetrating PeptideThe interplay of immunotherapy and chemotherapy: harnessing potential synergiesClinical Outcomes of Specific Immunotherapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis.SANTAVAC ™: A Novel Universal Antigen Composition for Developing Cancer Vaccines.Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progressPancreatic cancer-improved care achievableAwareness and understanding of cancer immunotherapy in Europe.Trial Watch: Peptide-based anticancer vaccines.The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantationNew targeted therapies in pancreatic cancer.Therapeutic vaccines for gastrointestinal cancers.The Anti-inflammatory Effect of GV1001 Mediated by the Downregulation of ENO1-induced Pro-inflammatory Cytokine Production.Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinomaThe National Cancer Institute's PREVENT Cancer Preclinical Drug Development Program: overview, current projects, animal models, agent development strategies, and molecular targetsAdjuvant and neoadjuvant systemic therapy for pancreas adenocarcinomaGenetic variations associated with gemcitabine treatment outcome in pancreatic cancer.Whole cell vaccination using immunogenic cell death by an oncolytic adenovirus is effective against a colorectal cancer model.A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea.Role of immune cells in pancreatic cancer from bench to clinical application: An updated reviewFrom Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic CancersCancer Vaccines: Enhanced Immunogenic Modulation through Therapeutic Combinations.Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells.Adjuvant HER2/neu peptide cancer vaccines in breast cancer.
P2860
Q26741736-932C9F7D-5A5A-4DC7-8EB7-6B08DB34E6E4Q26744271-39E9E29B-8616-4BB5-9984-37365B3FF3F6Q26747140-3F633EBE-CC34-47AD-B8E4-874E748D468FQ26747695-2217842E-4969-447C-A163-60BC041DDDB8Q26750440-7D5A7C4A-437E-43B5-95D5-8B0B2FDC64A3Q26751686-577CE3B8-45FA-4D28-B776-1F394B43713FQ26765123-871BBF03-01EB-4921-B603-F796D32BDBCEQ26774641-83185CA7-2214-45CA-B1DA-9605B0CA162CQ26775381-B8063C42-8244-46BA-9315-FBB89C85DBB9Q26776028-355ADE73-D41C-40E3-BB48-D3D3D1041C73Q26777085-A38BE836-A278-493E-A9B3-351D55A58DE4Q26781538-130AB036-DE73-4B4A-A4CD-FB3931A7865FQ26782583-A2CCBC90-7B88-4A96-966C-82466740E67FQ26796323-85EF5BAB-DFE9-4BC3-9232-9D60144F859FQ26799714-AF65481A-CC8C-4477-9F17-7E73A782A886Q28066228-9D80C2A1-B172-4FBD-9DF5-2217123AB94BQ28076133-A84476BA-F470-44A1-BB73-0EB986A3B1EBQ28081893-C26D4A94-580C-4BCB-87D9-3F555675717FQ30235405-CB8662CE-0B1F-4001-BE1D-8EE291AA0C44Q30250097-3B42DB56-152A-4B6F-8F64-E0F795DFEE8EQ33578086-CA021084-87BC-448A-A5FF-EE3566B0B859Q33593871-CF114D18-117C-41E2-9B38-46ACE5B69A6CQ34036659-CD0F4C56-01B8-4618-BFCA-CC8A8EF1FB05Q34291043-00F83EAA-950D-4D69-ACB4-8D05679EB073Q34483345-EA0437ED-E55C-4F1D-A705-257B4EDA3DBCQ34544862-997D5948-5433-41D9-AC43-BEE636060FE1Q35651453-1CDECD5B-D146-4EAB-A19F-A773345A85F6Q35691248-E1E4BCE8-999E-4D4F-9310-2694756E8B1CQ36427736-EC8FE223-59A1-40A1-835E-6AA9AE421843Q36661995-3184EE68-D42D-4376-92F6-AB35FB673F6DQ36682108-56332FFC-22B7-4738-A697-9DA9EF4844A9Q37191059-C7BAC69E-568D-4D52-9921-7E915431EF22Q37372466-60A95331-8ABE-4EC9-9812-09A403F47F3EQ37502453-2B8C7C84-DAF8-4DB3-8D2F-FE0B647FF305Q37582596-2DC54B25-8A87-47A6-ABF5-44CD77246975Q37606102-902DE286-D32E-4644-9FF2-58F5880BF5A4Q37631655-E328DE1E-1867-465E-ACF5-204FC20C5DFDQ38600417-DB7C12A4-2663-4C7C-AEE5-12BDBCAEDF4BQ38608986-222E59E6-8CC1-41DC-BCEE-9F37FFAA076DQ38633206-91B5E630-7B68-4A0B-A37B-5F8C1EA7044E
P2860
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Gemcitabine and capecitabine w ...... el, randomised, phase 3 trial.
@en
Gemcitabine and capecitabine w ...... el, randomised, phase 3 trial.
@nl
type
label
Gemcitabine and capecitabine w ...... el, randomised, phase 3 trial.
@en
Gemcitabine and capecitabine w ...... el, randomised, phase 3 trial.
@nl
prefLabel
Gemcitabine and capecitabine w ...... el, randomised, phase 3 trial.
@en
Gemcitabine and capecitabine w ...... el, randomised, phase 3 trial.
@nl
P2093
P50
P1433
P1476
Gemcitabine and capecitabine w ...... el, randomised, phase 3 trial.
@en
P2093
Alan Anthoney
Angel Garcia-Alonso
Angus Robinson
Caroline Archer
Charlotte Rawcliffe
David Propper
Dean Naisbitt
Fareeda Coxon
Gary Middleton
Gemma Nanson
P304
P356
10.1016/S1470-2045(14)70236-0
P50
P577
2014-06-19T00:00:00Z